Antianginal Beta‑Blockers and Calcium Channel Blockers
Introduction/Overview Ischemic heart disease remains a principal cause of morbidity and mortality worldwide, with angina pectoris serving as a frequent clinical manifestation.…
Topic Archive
Category: Uncategorized
Metabolic Modulators in Angina
1. Introduction/Overview Brief Introduction to the Topic Angina pectoris, a clinical manifestation of myocardial ischemia, remains a leading cause of morbidity worldwide.…
Drugs for Acute Heart Failure (Inotropes)
Introduction / Overview Acute heart failure (AHF) represents a critical, time‑dependent clinical syndrome in which the myocardium is unable to supply adequate…
Drugs for Chronic Heart Failure: ACE Inhibitors, Beta‑Blockers, and Aldosterone Antagonists
1. Introduction/Overview Chronic heart failure (CHF) represents a progressive syndrome in which the myocardium fails to maintain adequate circulating volume and pressure.…
Cardiac Glycosides (Digoxin)
Introduction Definition and Overview Cardiac glycosides constitute a class of natural compounds that exert potent effects on the cardiovascular system. Digoxin, a…
Class I Antiarrhythmics (Na⁺ Channel Blockers)
Introduction / Overview Class I antiarrhythmics constitute a prominent group of agents that modify cardiac excitability by inhibiting the fast voltage‑gated sodium channels…
Class II, III, and IV Antiarrhythmics
Introduction/Overview Antiarrhythmic agents are essential in the management of arrhythmias that threaten hemodynamic stability or predispose to sudden cardiac death. Among the…
HMG-CoA Reductase Inhibitors (Statins)
1. Introduction/Overview HMG‑CoA reductase inhibitors, commonly referred to as statins, constitute one of the most frequently prescribed classes of lipid‑lowering agents worldwide.…
Fibrates and Bile Acid Sequestrants
1. Introduction Definition and Overview Fibrates constitute a class of lipid‑modifying agents that primarily target triglyceride metabolism and, to a lesser extent,…
Cholesterol Absorption Inhibitors and PCSK9 Inhibitors
Introduction/Overview Elevated low‑density lipoprotein cholesterol (LDL‑C) remains a principal modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). In recent decades, therapeutic advances…